A Multiple Dose Escalation Study of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis Clinical Trial

Official title:

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Sequential, Multiple Dose Escalation Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01585233
• Other study ID #: 7163-CL-0107
• Status: Completed
• Phase: Phase 2
• Start date: April 30, 2012
• Est. completion date: January 7, 2015

Study information

• Verified date: February 2024
• Source: Astellas Pharma Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to explore the safety and tolerability of multiple doses of ASKP1240 compared to placebo and determine Pharmacokinetics and Pharmacodynamics in subjects with moderate to severe psoriasis.

Description:

Treatment with ASKP1240 or placebo will be over 4 weeks (Baseline/Day 1, Days 15 and Day 29) with 12 weeks of follow-up for a total of 16 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: January 7, 2015
• Est. primary completion date: June 30, 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Subject has a clinical diagnosis of moderate to severe plaque psoriasis for 6 months or longer with at least 5% or greater Body Surface Area (BSA) affected with plaque psoriasis

• Subject must be a candidate for phototherapy and/or systemic therapy

• Subject must agree to avoid prolonged exposure to the sun and avoid the use of tanning booths or other ultraviolet light sources during the study

• Female subject must be either:

• post-menopausal (defined as at least 1 year without any menses) prior to Screening, or

• premenarchal prior to Screening, or

• documented surgically sterile or status post hysterectomy (at least 1 month prior to Screening), or

• if of childbearing potential, must have a negative serum pregnancy test at Screening and if sexually active must be using highly effective contraception. All sexually active subjects will be required to use highly effective contraception consisting of two forms of birth control (one of which must be a barrier method) starting at Screening and throughout the study period and for 28 days [or 5 five half lives of the study drug whichever is longer] after final study drug administration.

• Female subject must not be lactating and must not be breastfeeding at Screening or during the study period and for 28 days [or 5 five half lives of the study drug whichever is longer] after final study drug administration.

• Female subject must not donate ova starting at Screening and throughout the study period and for 28 days [or 5 five half lives of the study drug whichever is longer] after final study drug administration.

• Male subject and their female spouse/partners who are sexually active must be using highly effective contraception1 consisting of two forms of birth control (one of which must be a barrier method) starting at Screening and continue throughout the study period and for 28 days [or 5 five half lives of the study drug whichever is longer] after final study drug administration.

• Male subject must not donate sperm starting at Screening and throughout the study period and for at least 28 days [or 5 five half lives of the study drug whichever is longer] after final study drug administration.

• Highly effective contraception is defined as:

• Established use of oral, injected or implanted hormonal methods of contraception.

• Placement of an intrauterine device (IUD) or intrauterine system (IUS)

• Barrier methods of contraception: Condom alone or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.

• Subject must be willing and able to comply with the study requirements, including prohibited concomitant medication restrictions.

• Waivers to the inclusion criteria will NOT be allowed.

Exclusion Criteria:

• Subject has non-plaque psoriasis (such as guttate, erythrodermic or pustular psoriasis)

• Subject has received treatment with systemic, non-biologic psoriasis therapy or other systemic immunosuppressant including investigational use of an approved agent within the last 30 days or 5 half-lives, whichever is longer, prior to the first dose of study drug

• Subject has ever been treated with efalizumab (Raptiva®)

• Subject has a total B lymphocyte count by flow cytometric determination that is less than the lower limit of normal

• Subject has a hemoglobin, that are below the lower limit

• Subject has a total white count, total lymphocyte count, total neutrophil count or total platelet that are below the lower limit

• Subject has any of the following lab values:

• ALT = 1.5 x upper limit of normal

• AST = 1.5 x upper limit of normal

• Total bilirubin = 1.5 x upper limit of normal

• Subject has previously received ASKP1240 or has participated in a study involving ASKP1240

• Subject has > 45 body mass index (BMI)

• Subject with a positive Tubercle Bacillus (TB) test who has not previously received adequate antimicrobial therapy for TB or is currently on, or is planned to start TB antimicrobial therapy

• Subject has abnormal chest x-ray indicative of acute or chronic lung disease

• Subject has uncontrolled intercurrent illness, including, but not limited to ongoing or active infection, any clinically significant cardiac disease seizure disorder, or psychiatric illness/social situations that would limit compliance with study requirements

• Subject has a history of any malignancy regardless of the location and the time of diagnosis in the last 5 years (including in-situ carcinoma of the cervix, but excluding successfully treated non-metastatic basal cell and squamous cell carcinoma)

• Subject has received live or live attenuated virus vaccinations within the last 30 days prior to first dose of study drug

• Subject has received treatment with another investigational drug within 30 days or 5 half-lives; whichever is longer, prior to the initiation of Screening

• Subject has a positive test for hepatitis B surface antigen (HBsAg) or hepatitis C (HCV) antibody

• Subject has a history of a positive test for human immunodeficiency virus (HIV) infection

• Subject has received treatment with systemic, biologic psoriasis therapy or other systemic immunosuppressant including investigational use of an approved agent within the last 56 days or 5 half-lives whichever is longer, prior to the first dose of study drug

• Waivers to the exclusion criteria will NOT be allowed.

Related Conditions & MeSH terms

• Psoriasis

Intervention

Drug:
• ASKP1240
Intravenous
• Placebo
Intravenous

Locations

Country	Name	City	State
Australia	CMAX	Adelaide	Victoria
Australia	Specialist Connect	Brisbane	Queensland
Australia	Linear Research	Nedlands	Western Australia
Australia	Epworth Hospital	Richmond	Victoria
Canada	Ultranova Skincare	Barrie	Ontario
Canada	Durondel C.P. Inc, The Dermatology Clinic	Moncton	New Brunswick
Canada	Innovaderm Research, Inc.	Montreal	Quebec
Canada	New Lab Clinical Research	St. John's	Newfoundland and Labrador
Canada	K. Papp Clinical Research	Waterloo	Ontario
New Zealand	Auckland Clinical Studies	Auckland
New Zealand	Christchurch Clincial Studies Trust, Ltd.	Christchurch
New Zealand	P3 Research, Tauranga	Tauranga
New Zealand	P3 Research, Wellington	Wellington

Sponsors (2)

Lead Sponsor	Collaborator
Astellas Pharma Global Development, Inc.	Kyowa Kirin Co., Ltd.

Countries where clinical trial is conducted

Australia,  Canada,  New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetics of ASKP1240: Area under the curve 0-336 (AUC336 )		Day 1 to Day 113 (12 visits)
Primary	Pharmacokinetics of ASKP1240: Maximum Concentration (Cmax)		Day 1 to Day 113 (12 visits)
Primary	Pharmacodynamic variable: CD40 receptor occupancy on peripheral blood B cells		Day 1 to Day 113 (12 visits)
Primary	Characterize safety profile of ASKP1240 through adverse event reporting, vital signs, clinical laboratory evaluations, physical examinations and 12-lead electrocardiograms (ECGs)		113 Days
Secondary	Mean change from baseline to 8 weeks in Psoriasis Area Severity Index (PASI) score		Baseline and 8 weeks
Secondary	Mean change from baseline to 8 weeks in Physicians Static Global Assessment (PSGA) score		Baseline and 8 weeks
Secondary	Proportion of Subjects Achieving Treatment Success	Success of the treatment of psoriasis is defined as a score of 1 (almost clear) or 0 (clear) as measured by the PSGA	8 weeks
Secondary	Mean change from baseline to 8 weeks in % Body Surface Area (BSA)		Baseline and 8 weeks
Secondary	Cytokine Concentration		Day 1 to Day 113 (9 visits)
Secondary	Anti-ASKP1240 antibodies		Day 1 to Day 113 (8 visits )
Secondary	Lymphocyte subset quantitation		Day 1 to Day 113 (9 visits)

External Links

•   Link to plain language summary of the study on the Trial Results Summaries website
•   Link to results and other applicable study documents on the Astellas Clinical Trials website